

TREATMENT OF MYOCARDIAL INFARCTION

The CNIO has developed compositions and methods useful for the treatment and prevention of conditions associated with myocardial infarction.

Industrial partners are being sought to collaborate through a patent license agreement for the development and exploitation of the technology.

Description

The inventors have found a novel method for the treatment of myocardial infarction based in non integrative virus vectors, for example, adeno-associated viral vectors (AAV) encoding for telomerase reverse transcriptase (TERT).

Main innovations and advantages

The inventors have found that the vectors of the invention are useful in the treatment of myocardial infarction, for example, in tissue damage resulting from myocardial infarction, fibrosis of the myocardium resulting from myocardial infarction, and reducing cardiac function resulting from myocardial infarction.

Using non-integrative viral vectors, such as AAV, seems to be particularly advantageous. For example, non-integrative vectors do not cause any permanent genetic modification; the vectors target to adult tissues, avoiding having the subjects under the effect of constitutive telomerase expression from early stages of development, and additionally, non-integrative vectors

effectively incorporate a safety mechanism to avoid over-proliferation of TERT expressing cells. .

Intellectual property

Patent title :

“Telomerase reverse transcriptase-based therapies for treatment of conditions associated with myocardial infarction”


Applicant: Spanish National Cancer Research Center (CNIO) and Universitat Autònoma de Barcelona (UAB).

International patent application:

WO2016020346

Patent granted in:

Europe, Japan and USA.



For more information, please contact:

Technology Transfer and Valorization Office
Centro Nacional de Investigaciones Oncológicas
C/ Melchor Fernández Almagro, 3
28029 Madrid Spain
technologytransfer@cnio.es
www.cnio.es
@CNIO_Cancer